CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation
Authors
Avolio A. W. (ORCID:0000-0003-2491-7625)
Francica G.
+3 more
Iezzi R.
Pompili M. (ORCID:0000-0001-6699-7980)
Ponziani F. R. (ORCID:0000-0002-5924-6238)
Publication date
1 January 2013
Publisher
'Baishideng Publishing Group Inc.'
Doi
Cite
View
on
PubMed
Abstract
Several therapeutic procedures have been proposed as bridging treatments for patients with hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). The most used treatments include transarterial chemoembolization and radiofrequency ablation. Surgical resection has also been successfully used as a bridging procedure, and LT should be considered a rescue treatment in patients with previous HCC resection who experience tumor recurrence or post-treatment severe decompensation of liver function. The aims of bridging treatments include decreasing the waiting list dropout rate before transplantation, reducing HCC recurrence after transplantation, and improving post-transplant overall survival. To date, no data from prospective randomized studies are available; however, for HCC patients listed for LT within the Milan criteria, prolonging the waiting time over 6-12 mo is a risk factor for tumor spread. Bridging treatments are useful in containing tumor progression and decreasing dropout. Furthermore, the response to pre-LT treatments may represent a surrogate marker of tumor biological aggressiveness and could therefore be evaluated to prioritize HCC candidates for LT. Lastly, although a definitive conclusion can not be reached, the experiences reported to date suggest a positive impact of these treatments on both tumor recurrence and post-transplant patient survival. Advanced HCC may be downstaged to achieve and maintain the current conventional criteria for inclusion in the waiting list for LT. Recent studies have demonstrated that successfully downstaged patients can achieve a 5-year survival rate comparable to that of patients meeting the conventional criteria without requiring downstaging. © 2013 Baishideng Publishing Group Co., Limited. All rights reserved
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
PubliCatt
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:publicatt.unicatt.it:10807...
Last time updated on 17/09/2019
PubliCatt
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:publicatt.unicatt.it:10807...
Last time updated on 23/02/2014